Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.

The transmitter is placed on the skin on top of the implanted sensor ... integrate with compatible medical devices, including insulin pumps, as part of an automated insulin delivery system.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

Continuous blood glucose monitors, which are inserted just under the skin, or implanted in the body, can connect to smartphones, or to insulin pumps, avoiding the need for people to do regular ...